Research and Development

AbbVie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own …

Joining its current indication as a treatment for rheumatoid arthritis and cryopyrin-associated periodic syndromes, Sobi’s Kineret has been given approval …

Pfizer has revealed that it has shut down a trial of its vascular endothelial growth factor (VEGF) inhibitor Inlyta (axitinib) …

Alexion Pharmaceuticals is badly in need of alternative revenue streams to Soliris, its mega-blockbuster that could start to face competition …

Mylan has taken several steps recently that seem intended to hit sales of its big rivals on their key products, …

Closely following the news that Keytruda (pembrolizumab) had failed in the treatment of unresectable or metastatic melanoma as a combination …

A new study conducted at the University of Eastern Finland and the German Center for Neurodegenerative Diseases (DZNE) has revealed …

The oncology field moves so quickly that it can be hard to keep track of the latest innovations. Ben Hargreaves …

A report conducted by charity Orchid has revealed a “worrying trend” in the treatment of prostate cancer, indicating that as …

Shares in biopharma firm Incyte were sent reeling by as much as 20% when the company announced that the results …

Some of the biggest news this week concerns companies that are looking to move on parts of their business, but …

Norwegian biopharmaceutical firm Nordic Nanovector has revealed that its Chief Executive Officer Luigi Costa is set to step down from …

Fred van Goor, Principle Research Fellow at Vertex Pharmaceuticals, discusses his history of work in cystic fibrosis and how the …

UK drug watchdog NCIE has issued draft guidance rejecting the routine use of Sanofi’s Dupixent (dupilumab) for the treatment of …

28 years after the US first pioneered proton beam therapy at Loma Linda University Medical Center, the UK now has …